Skip to main content

Associate Professor of Medicine, Division of Cardiology
Director, Cardiac Catheterization Lab
Program Director, Interventional Cardiology Fellowship
Co-Director of Cardiology Clinical Trials

Specialty Areas

Interventional cardiology; Left atrial appendage occlusion for patients with atrial fibrillation; Atrial septal defect (ASD) and patent foramen ovale (PFO), complex coronary artery disease and cardiogenic shock, coronary atherectomy and chronic total occlusions.

Education and Experience

BS: University of Illinois, 1996;
MD: University of Illinois – Chicago College of Medicine, 2001;
Internship: Northwestern University, 2001-2002;
Residency: Northwestern University, 2002-2004;
Fellowship in Cardiovascular Disease: Northwestern University, 2004-7;
Fellowship in Interventional Cardiology: Northwestern University, 2007-2008;
MS in Clinical Investigation: Northwestern University, 2008;
Assistant Professor of Medicine and Director of Clinical Research, UNC Hospitals, 2008-2011;
Interventional Cardiology, St. Vincent Medical Group, Indianapolis, IN, 2011-2015;
Director, Cardiac Catheterization Lab, UNC Hospitals – 2016- present

Clinical and Research Interests

Dr. Rossi is the Director of the Cardiac Catheterization Lab at the University of North Carolina. He specializes in the treatment of complex coronary artery disease, and endovascular devices for the prevention of stroke in patients with atrial fibrillation. He is an active researcher with special interest in genetic testing to improve outcomes for patients following coronary stent placement, and the use of new technology to perform endovascular procedures.

Board Certifications

Internal Medicine (2004, recertified 2014)
Cardiovascular Disease (2007, recertified 2017)
Interventional Cardiology (2008, recertified 2018)

Selected Bibliography

Another Chapter in the Continuing Saga of “Precision Percutaneous Coronary Intervention.” Stouffer GA, Madan S, Rossi JS. . JACC Cardiovasc Interv. 2018 Aug 13;11(15):1479-1481.

Review of clopidogrel dose escalation in the current era of potent P2Y12 inhibitors. Howell LA, Stouffer GA, Polasek M, Rossi JS. . Expert Rev Clin Pharmacol. 2015;8(4):411-21. Epub 2015 Jun 19. Review.

Clopidogrel dose adjustment after outpatient screening for CYP2C19 variant alleles: a pilot study. Rossi JS, Cammarata M, Dharmavaram J, Weck K, Walko C, Gabriel D, Kuritzky J, Muldrew K, Stouffer GA.. Pharmacogenomics 2014 May;15(7):915-23. doi: 10.2217/pgs.14.17.

Implementation and evaluation of a CYP2C19 genotype-guided antiplatelet therapy algorithm in high-risk coronary artery disease patients. Lee JA, Lee CR, Reed BN, Plitt DC, Polasek MJ, Howell LA, Cicci JD, Tasca KE, Weck KE, Rossi JS, Stouffer GA. . Pharmacogenomics. 2015;16(4):303-13.

Evaluating the effectiveness of a rapidly adopted cardiovascular technology with administrative data: the case of drug-eluting stents for acute coronary syndromes. Federspiel JJ, Stearns SC, Sheridan BC, Kuritzky JJ, D’Arcy LP, Crespin DJ, Carey TS, Rossi JS.. Am Heart J. 2012 Aug;164(2):207-14. doi: 10.1016/j.ahj.2012.05.016.

Stress imaging use and repeat revascularization among medicare patients with high-risk coronary artery disease. Am J Cardiol Rossi JS, Federspiel JJ, Crespin DJ, Carey TS, Sheridan BC, Stearns SC.. 2012 Nov 1;110(9):1270-4. doi: 10.1016/j.amjcard.2012.06.029. Epub 2012 Jul 21.

Three-year outcomes of multivessel revascularization in very elderly acute coronary syndrome patients. Sheridan BC, Stearns SC, Rossi JS, D’Arcy LP, Federspiel JJ, Carey TS..Ann Thorac Surg. 2010 Jun;89(6):1889-94; discussion 1894-5. doi: 10.1016/j.athoracsur.2010.03.003


Dr. Joseph Rossi